Sera Prognostics Inc. is a biotechnology company specializing in predictive diagnostic tests for pregnancy-related complications. The company focuses on developing and commercializing blood-based tests that help assess a pregnant patient’s risk for conditions such as preterm birth, preeclampsia, and other adverse outcomes. By applying proteomic and analytic technologies, Sera Prognostics aims to provide clinicians with actionable risk assessments that can support more informed decisions around monitoring, intervention, and allocation of maternal-fetal care resources. Its products are designed to be used within routine prenatal care, serving obstetric practices, health systems, and payers that seek to improve maternal and neonatal health outcomes while managing costs associated with high-risk pregnancies. Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics operates at the intersection of diagnostics, obstetrics, and population health management within the healthcare and life sciences markets.